New study aims to spot which kids with rare brain inflammation will recover fully
NCT ID NCT07188194
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 32 children diagnosed with their first episode of acute disseminated encephalomyelitis (ADEM), a rare brain inflammation that usually follows an infection. Researchers will check if early MRI scans, spinal fluid tests, and symptoms can predict which children will recover fully and which might develop lasting problems or other conditions like multiple sclerosis. The goal is to better understand the disease and improve care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which children with ADEM need more aggressive treatment early on, potentially improving recovery.
What could go wrong
This is a small, early observational study (32 participants) that only looks for patterns—it does not test any treatment. Results may not apply to all children with ADEM.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DISSEMINATED ENCEPHALOMYELITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••